Brief: Biofrontera To Launch Phase 3 Clinical Study Evaluating Ameluz®-Pdt For The Treatment Of Actinic Keratosis On The Extremities, Neck And Trunk
21/11/2022 14:40
Nov 21 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA TO LAUNCH PHASE 3 CLINICAL STUDY EVALUATING
AMELUZ®-PDT FOR THE TREATMENT OF ACTINIC KERATOSIS ON THE
EXTREMITIES, NECK AND TRUNK
* BIOFRONTERA INC - INITIALLY 11 CLINICAL TRIAL SITES IN
U.S. WILL
PARTICIPATE
* BIOFRONTERA INC - WILL ENROLL APPROXIMATELY 165 PATIENTS
STRATIFIED BY BODY REGION
* BIOFRONTERA INC - STUDY IS BEING MANAGED BY BIOFRONTERA
BIOSCIENCE GMBH
Source text for Eikon: ID:nGNXbgrpmX
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales